A 4-year-old girl with unremitting chronic mucocutaneous candidiasis since 9 months of age was treated topically with haloprogin for a total of 460 days in seven periods of consecutive weeks to months over a 3-year span. During that time, she was given 403 tubes or bottles (30 gm or ml) amounting to about 12,090 gm of a product containing 1% haloprogin. Biochemical, hematologic, and urine examinations were used in monitoring the patient's condition during treatment and showed no evidence of systemic or dermal toxicity.